Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Survey Assessing the Factors of Treatment Intensification in Uncontrolled Hypertensive Patients Under a Combination Therapy, Either Fixed or Not, of a Renin-Angiotensin System Blocker (RASB) and Hydrochlorothiazide (HCTZ), According to Their Level of Cardiovascular Risk.

NCT01071681 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01071681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01071681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Survey Assessing the Factors of Treatment Intensification in Uncontrolled Hypertensive Patients Under a Combination Therapy, Either Fixed or Not, of a Renin-Angiotensin System Blocker (RASB) and Hydrochlorothiazide (HCTZ), According to Their Level of Cardiovascular Risk.
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
November 30, 2009
Completion date
September 30, 2010
Enrollment
1,589 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arterial hypertension